The era of personalized medicine for advanced-stage non-small-cell lung cancer (NSCLC)
began when biomarker-based evidence of molecular pathway and/or oncogene addiction of …

Rapidly developing molecular biology techniques have been employed to identify cancer
driver genes in specimens from patients with non-small cell lung cancer (NSCLC). Inhibitors …

Background We did a phase 2 trial of pembrolizumab in patients with non-small-cell lung
cancer (NSCLC) or melanoma with untreated brain metastases to determine the activity of …

Background RET fusions are present in 1%–2% of non-small cell lung cancer (NSCLC).
Pralsetinib, a highly potent, oral, central nervous system-penetrant, selective RET inhibitor …

Background Although EGFR mutant tumors exhibit low response rates to immune
checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; …

Introduction Although frequent in NSCLC, patients with brain metastases (BMs) are often
excluded from immune checkpoint inhibitor (ICI) trials. We evaluated BM outcome in a less …

Many decades in the making, immunotherapy has demonstrated its ability to produce
durable responses in several cancer types. In the last decade, immunotherapy has shown …

Liquid biopsy refers to the analysis of any tumour-derived material circulating in the blood or
any other body fluid. This concept is particularly relevant in lung cancer as the tumour is …

Purpose The metabolic changes associated with cachexia–sarcopenia syndrome might
down-regulate antitumor immunity. We hypothesized that this syndrome reduces efficiency …

METHODS In this retrospective study, patients from Memorial Sloan Kettering Cancer Center
with RET-rearranged lung cancers diagnosed between 2009 and 2017 were identified …